Selank is a synthetic heptapeptide — a short seven-amino-acid chain — developed in Russia at the Institute of Molecular Genetics of the Russian Academy of Sciences together with the V. V. Zakusov Institute of Pharmacology. Unlike molecules borrowed from other species, Selank was engineered from a human building block: it is a stabilized analogue of tuftsin, a naturally occurring peptide long known for its immunomodulatory activity. Researchers took the core tuftsin sequence (Thr-Lys-Pro-Arg) and added a Pro-Gly-Pro fragment to slow its breakdown, producing a molecule that survives longer in biological systems while retaining tuftsin-like signaling.
What keeps Selank in the research literature is the unusual combination of activities attributed to it. In laboratory and preclinical work it has been described as an anxiolytic (anti-anxiety) agent, a nootropic (cognition-related) compound, and an immunomodulator — all without the sedation and dependence associated with classic tranquilizers in those same models. This guide summarizes what the peer-reviewed literature reports, and where the evidence is still thin.
Tuftsin is a small endogenous peptide historically studied for its effects on the immune system, including macrophage activity. Its major limitation as a research tool is fragility — it is degraded quickly. Selank's design addresses this directly: the appended Pro-Gly-Pro tail improves metabolic stability, which is one reason the molecule has been investigated as an intranasally administered research peptide in the originating studies. Because Selank sits on the tuftsin scaffold, work on it has spanned two worlds that rarely overlap — neuropharmacology and immunology — and much of the interest comes from the observation that a single small peptide appears to touch both.
The most frequently cited property of Selank is anxiolytic-like activity. In animal and cell studies it has been compared to benzodiazepines such as diazepam, with reports describing a similar direction of effect on anxiety-related behavior — but, importantly, without the amnesia, sedation or dependence typically linked to that drug class in the same models. This "benzodiazepine-like effect without the classic drawbacks" framing is a recurring theme in the Selank literature, and it is a large part of why the peptide became a reference compound in peptide-anxiolytic research. In the originating Russian program it was also studied in the context of generalized anxiety and asthenic states; robust, independent human trials outside of Russia remain limited.
Selank does not appear to act like a simple receptor agonist. Instead, research points toward modulation of signaling systems, with several threads standing out:
Because Selank descends from tuftsin, its immune-related signaling has been examined as well. Tuftsin's classical role is immunomodulatory, and the literature on Selank references effects consistent with that lineage — for example, influence on cytokine balance and immune signaling in model systems. As with the neurological findings, these are laboratory observations that illustrate why the peptide is studied across disciplines, not demonstrations of a clinical immune benefit in people.
This is the part a responsible sourcing page should state plainly. The preclinical evidence for Selank is real and reasonably deep: there are peer-reviewed cell and animal studies of its effects on GABAergic gene expression, BDNF and behavior, and a substantial body of originating Russian research on its anxiolytic profile.
However, large, independent, controlled human clinical trials are limited, and most of the human data originate from Russia. Selank has not been approved by the U.S. Food and Drug Administration, is not an approved drug in the United States or the European Union, and is not established as safe or effective for any human use. A great deal of the enthusiasm around Selank comes from mechanistic and preclinical work; which of those effects translate to robust, reproducible human outcomes — and under what conditions — remains an open research question. Treating preclinical findings as proven human benefits is exactly the mistake this field is prone to, and we won't make it here.
For research applications, identity and purity are what separate a usable reference compound from an unknown. The Selank we supply to the research community is a lyophilized powder tested to high purity by HPLC, with a third-party Certificate of Analysis (COA) available for each lot, strictly for in-vitro laboratory use:
New to handling lyophilized peptides? See our Research Center for storage, reconstitution and COA guidance.
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a stabilized analogue of tuftsin, a naturally occurring immunomodulatory peptide, and has been studied in the laboratory for anxiolytic, nootropic and immunomodulatory activity.
In laboratory research Selank has been reported to modulate the expression of genes involved in GABAergic neurotransmission and to influence brain-derived neurotrophic factor (BDNF) in regions such as the hippocampus and prefrontal cortex. These are mechanisms observed in cell and animal models, not established human clinical outcomes.
No. Selank is not approved by the FDA and is not a drug in the United States. Material sold for laboratory research is strictly for in-vitro and analytical use only and is not for human or animal consumption. Human clinical evidence outside Russia is limited.
Selank is built on the tuftsin sequence (Thr-Lys-Pro-Arg) with an additional Pro-Gly-Pro fragment added to increase stability. Tuftsin is an endogenous peptide known for immunomodulatory activity, which is why Selank has been studied for both nervous-system and immune-related effects.